Unicycive Therapeutics, Inc. (UNCY) — Financial statements
Income statement, balance sheet, and cash flow for Unicycive Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 0.68↓29.0% | 0.95 | 0.00 | |
| Cost of Revenue | 0.57 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.57 | 0.00↓100.0% | 0.68↓29.0% | 0.95 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 9↓54.4% | 20↑55.1% | 13↑3.7% | 12↑104.5% | 6 | |
| General & Administrative Expenses | 20↑68.5% | 12↑41.6% | 9↑30.2% | 7↑126.7% | 3 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 20↑68.5% | 12↑41.6% | 9↑30.2% | 7↑126.7% | 3 | |
| Other Expenses | -0.57 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 29↓9.9% | 32↑49.7% | 21↑12.9% | 19↑111.7% | 9 | |
| Total Costs & Expenses | 30↓8.1% | 32↑49.7% | 21↑12.9% | 19↑111.7% | 9 | |
| Operating Results | ||||||
| Operating Income | -30↑8.1% | -32↓54.6% | -21↓15.1% | -18↓101.1% | -9 | |
| Depreciation & Amortization | 0.57↑33.6% | 0.43↑50.7% | 0.28↑76.4% | 0.16↑1138.5% | 0.01 | |
| EBITDA | -26↑28.5% | -36↓20.1% | -30↓68.7% | -18↓90.8% | -9 | |
| EBIT | -26↑27.8% | -37↓20.3% | -30↓68.7% | -18↓92.3% | -9 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.94↓20.9% | 1↑123.3% | 0.53↑8983.3% | -0.01↑99.0% | -0.63 | |
| Interest Income | 1↓19.7% | 1↑105.0% | 0.62 | 0.00 | 0.00 | |
| Interest Expense | 0.07↑0.0% | 0.07↓13.4% | 0.08↑1266.7% | 0.01↓99.0% | 0.63 | |
| Non-Operating Income | -3↓166.8% | 5↓53.1% | 10 | 0.00↓100.0% | 0.41 | |
| Other Income / Expenses | 3↑164.2% | -5↑52.8% | -10↓162733.3% | -0.01↑99.4% | -1 | |
| Income Before Tax | -27↑27.7% | -37↓20.2% | -31↓69.1% | -18↓80.3% | -10 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -27↑27.7% | -37↓20.2% | -31↓69.1% | -18↓80.3% | -10 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -27↑27.7% | -37↓20.2% | -31↓69.1% | -18↓80.3% | -10 | |
| Bottom-Line Net Income | -27↑29.8% | -38↓20.4% | -31↓73.9% | -18↓80.3% | -10 | |
| EPS (Basic) | -1.67↑70.2% | -5.60↓337.5% | -1.28↓6.7% | -1.20↑86.0% | -8.60 | |
| EPS (Diluted) | -1.67↑70.2% | -5.60↓337.5% | -1.28↓6.7% | -1.20↑86.0% | -8.60 | |
| Weighted Average Shares | 159↑2271.7% | 7↑173.0% | 2↑63.0% | 2↑29.0% | 1 | |
| Weighted Average Diluted Shares | 159↑2271.7% | 7↑173.0% | 2↑63.0% | 2↑29.0% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.